UNASSIGNED: Neurodevelopmental alterations and @entity73 are constant features of Down syndrome (DS), a @entity74 due to triplication of chromosome 21. @entity38756 is one of the triplicated genes that is thought to be strongly involved in brain alterations. Treatment of @entity38756 @entity19 with @entity3089 ( @entity3090 ), an inhibitor of @entity38756 , improves cognitive performance, suggesting that @entity3090 may represent a suitable treatment of DS. Evidence in the @entity20213 @entity19 model of DS shows that @entity3090 restores hippocampal development, although this effect is ephemeral. Other studies, however, show no effects of treatment on hippocampus-dependent memory. On the other hand, a pilot study in young adults with DS shows that @entity3090 transiently improves some aspects of memory. Interestingly, @entity3090 plus cognitive training engenders effects that are more prolonged. Studies in various rodent models show a positive impact of @entity3090 on brain and behavior, but other studies show no effect. In spite of these discrepancies, possibly due to heterogeneity of protocols/timing/species, @entity3090 seems to exert some beneficial effects on the brain. It is possible that protocols of periodic @entity3090 administration to individuals with DS (alone or in conjunction with other treatments) may prevent the disappearance of its effects.

@entity3089 : A useful therapy for XXXX in Down syndrome?

@entity19 :: ('10090', 'Species') :: ['mouse', 'transgenic mice'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive disability'] @entity3089 :: ('MESH:C045651', 'Chemical') :: ['epigallocatechin gallate'] @entity3090 :: ('CHEBI:4806', 'Chemical') :: ['EGCG'] @entity20213 :: ('21101(Tax:10090)', 'Gene') :: ['Ts65Dn'] @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic condition'] @entity38756 :: ('13548(Tax:10090)', 'Gene') :: ['Dyrk1A', 'DYRK1A']
@entity73 :: (MESH:D003072,Disease) :: ['cognitive disability']
